Avexa Closes ATC’s Phase III Trial To Evaluate Data

Avexa Limited (ASX:AVX) announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.

Source: Avexa Closes ATC’s Phase III Trial To Evaluate Data